In this free webinar, gain insights into advancements in cardiovascular clinical development and treatments in response to the increasing incidence of type 2 diabetes mellitus (T2DM) and cardiovascular diseases. The featured speakers will discuss successful study outcomes in developing GLP1s in new therapeutic areas within cardiovascular medicine. Attendees will learn about the importance of diversifying clinical trial participants to address healthcare disparities and increase access for underserved populations with cardiovascular diseases. The speakers will also discuss the moral, scientific and regulatory requirements to ensure equitable access to cardiovascular clinical trials.
TORONTO, Nov. 28, 2023 /PRNewswire-PRWeb/ -- In this webinar, the panel of experts will discuss recent advancements in cardiovascular clinical development. The incidence and prevalence of type 2 diabetes mellitus (T2DM) and cardiovascular diseases such as heart failure are increasing worldwide, resulting in the need to not only bring forward new treatments but to better understand existing treatments, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and their potential applications in cardiovascular disease and cardiovascular kidney metabolic (CKM) syndrome.
Future successful study outcomes will depend on applying lessons learned over the last 20 years of developing GLP-1s to new therapeutic areas in cardiovascular disease, as well as exploring cardiac and renal endpoints in non-diabetic patients, both with and without cardiovascular disease.
The featured speakers will also discuss the increasing moral, scientific and regulatory requirements to increase access to cardiovascular clinical trials for populations historically underserved by the clinical research community since these diseases disproportionately impact disadvantaged and minority populations. The panel will consider efforts to diversify clinical trials in the cardiovascular space and explore what else should be done to meet this need.
Join this webinar to gain an understanding of the potential application of GLP-1 RAs in the treatment of cardiovascular indications, how the landscape for cardiovascular clinical research is changing, and what this means for the future of cardiovascular clinical trials.
Join experts from the clinical research business of Thermo Fisher Scientific, Adrienne Richards, MD, Medical Science and Strategy Lead, Cardiovascular; Rose Blackburne, MD, Therapeutic Area Head, Medical Science and Strategy; Marlena Erikson, Senior Director, Project Oversight; and Paul Collins (moderator), Executive Director and Cardiovascular Pillar Head, for the on Wednesday, December 6, 2023, at 11am EST (4pm GMT/UK).
For more information, or to register for this event, visit .
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit
For information about hosting a webinar visit
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, vkovacevic@xtalks.com
SOURCE Xtalks
Share this article